Impact of rituximab on COVID-19 outcomes
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00277-021-04662-1.pdf
Reference26 articles.
1. Sette A, Crotty S (2021) Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184(4):861–880. https://doi.org/10.1016/j.cell.2021.01.007
2. RydyznskiModerbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D et al (2020) Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183(4):996–1012. https://doi.org/10.1016/j.cell.2020.09.038
3. McLaughlin P, Grillo-Lopez AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825–2833. https://doi.org/10.1200/JCO.1998.16.8.2825
4. Aksoy S, Dizdar O, Hayran M, Harputluoglu H (2009) Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leukemia Lymphoma 50(3):357–365. https://doi.org/10.1080/10428190902730219
5. Pujadas E, Ibeh N, Hernandez MM, Waluszko A, Sidorenko T, Flores V et al (2020) Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. J Med Virol 92(9):1695–1698. https://doi.org/10.1002/jmv.25988
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A maintenance hemodialysis patient complicated with hypogammaglobulinemia presenting typical COVID-19 pneumonia CT findings: a case report;Renal Replacement Therapy;2024-01-22
2. Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency;The Journal of Allergy and Clinical Immunology: In Practice;2024-01
3. COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients;Scientific Reports;2023-12-01
4. Antibody responses to SARS‐CoV‐2 Omicron infection in patients with hematological malignancies: A multicenter, prospective cohort study;Journal of Medical Virology;2023-12
5. T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19;Science Translational Medicine;2023-11-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3